<DOC>
	<DOC>NCT02410512</DOC>
	<brief_summary>This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and Atezolizumab with or without bevacizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy, or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for which a clinical trial of an investigational agent is a recognized standard of care.</brief_summary>
	<brief_title>A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab With or Without Bevacizumab in Participants With Locally Advanced or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients 18 years of age or older Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Life expectancy of at least 12 weeks Adequate hematologic and end organ function Histologic documentation of locally advanced, recurrent or metastatic incurable solid malignancy that has progressed after available standard therapy, or for which standard therapy is ineffective, intolerable, or considered inappropriate; or for which a clinical trial of an investigational agent is recognized standard of care Tumor specimen availability Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) Any anticancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment Malignancies other than disease under study within 5 years prior to Cycle 1, Day 1 Primary central nervous system (CNS) malignancy, or untreated/active CNS metastase Leptomeningeal disease History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted History of autoimmune disease Positive human immunodeficiency virus (HIV) test Active hepatitis B or C, or tuberculosis Severe infection within 4 weeks prior to randomization Prior allogenic bone marrow or solid organ transplantation Significant cardiovascular disease Known clinically significant liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>